Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets
The company's diagnostic platform utilizes its High Throughput Screening (HTS) facility, located in Israel.
- The company's diagnostic platform utilizes its High Throughput Screening (HTS) facility, located in Israel.
- It is designed for cancer patients who seek the optimal cannabinoid composition.
- Once exposed to the cannabinoid compositions, the cancer cells are monitored for apoptotic and necrotic effects.
- For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.